Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TGZKY
ADC Name
AMT-151
Synonyms
AMT 151; AMT-151; AMT151
   Click to Show/Hide
Organization
Multitude Therapeutics, Inc.
Drug Status
Phase 1
Indication
In total 7 Indication(s)
Breast cancer
Phase 1
Clinical Trial
Endometrial cancer
Phase 1
Clinical Trial
Lung cancer
Phase 1
Clinical Trial
Ovarian cancer
Phase 1
Clinical Trial
Pancreatic cancer
Phase 1
Clinical Trial
Pleura mesothelioma
Phase 1
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Ab-151
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
Duostatin 5
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05498597
Phase 1
First-in-human, phase 1 study of AMT-151, an anti-folate receptor alpha antibody-drug conjugate, in patients with selected advanced solid tumours.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05498597  Clinical Status Phase 1
Clinical Description First-in-human, phase 1 study of AMT-151, an anti-folate receptor alpha antibody-drug conjugate, in patients with selected advanced solid tumours.
References
Ref 1 First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours, NCT05498597